Advances in understanding the genetic basis of rheumatoid arthritis and osteoarthritis: Implications for therapy

American Journal of PharmacoGenomics

Volumn 2, Issue 4, 2002, Pages 223-234

  Chernajovsky, Yuti ^a   Winyard, Paul G ^a   Kabouridis, Panagiotis S ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CATALASE; CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE; ESTROGEN RECEPTOR; GAMMA INTERFERON; GLUCOCORTICOID; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; NITRIC OXIDE SYNTHASE; ONCOSTATIN M; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STEROID RECEPTOR; SUPEROXIDE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR; FREE RADICAL;

CATABOLISM; DISEASE COURSE; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; EXTRACELLULAR MATRIX; GENE INTERACTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC SUSCEPTIBILITY; HEREDITY; HLA SYSTEM; HUMAN; INTRACELLULAR SPACE; JOINT CAVITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RECEPTOR GENE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; GENOMICS; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALIA;

ANIMALS; ARTHRITIS, RHEUMATOID; CYTOKINES; FREE RADICALS; GENOMICS; HUMANS; OSTEOARTHRITIS; SIGNAL TRANSDUCTION;

EID: 0036445429     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200202040-00002     Document Type: Review

References (117)

1. Cush J, Kavanaugh A, Olsen N, et al. Rheumatology: Diagnosis and Therapeutics. Baltimore (MD): Williams and Wilkins. 1999
2. Leppavuori J, Kujala U, Kinnunen J, et al. Genome scan for predisposing loci for distal interphalangeal joint osteoarthritis: Evidence for a locus on 2q. Am J Hum Genet 1999; 65: 1060-7
3. Gregersen PK. Genetics of rheumatoid arthritis: Confronting complexity. Arthritis Res 1999; 1 (1): 37-44
4. Masi AT, Bijlsma JW, Chikanza IC, et al. Neuroendocrine, immunologic, and microvascular systems interactions in rheumatoid arthritis: Physiopathogenetic and therapeutic perspectives. Semin Arthritis Rheum 1999; 29 (2): 65-81
5. Masi AT. Hormonal and immunologic risk factors for the development of rheumatoid arthritis: An integrative physiopathogenetic perspective. Rheum Dis Clin North Am 2000; 26 (4): 775-803
6. Elliott M, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFa. Arthritis Rheum 1993; 36: 1681-9
7. Neidhart M, Rethage J, Kuchen S, et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: Association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum 2000; 43 (12): 2634-47
8. Singal DP, Li J, Zhu Y. Genetic basis for rheumatoid arthritis. Arch Immunol Ther Exp 1999; 47 (5): 307-11
9. Singal DP, Li J, Zhu Y. HLA class III region and susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 2000; 18 (4): 485-91
10. Holmdahl R. Association of MHC and rheumatoid arthritis. Why is rheumatoid arthritis associated with the MHC genetic region?: An introduction. Arthritis Res 2000; 2 (3): 203-4
11. Matsushita M, Tsuchiya N, Oka T, et al. New polymorphisms of human CD80 and CD86: Lack of association with rheumatoid arthritis and systemic lupus erythematosus. Genes Immun 2000; 1 (7): 428-34
12. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991; 10 (13): 4025-31
13. Kollias G. Tumour necrosis factor: A specific trigger in arthritis. Res Immunol 1993; 144 (5): 342-7
14. Georgopoulos S, Plows D, Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996; 46 (2): 86-97
15. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997; 27 (10): 2588-92
16. Brennan FM, Gibbons DL, Cope AP, et al. TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: Evidence of feedback control of TNF action. Scand J Immunol 1995; 42 (1): 158-65
17. Jacob C, Fronek Z, Lewis G. Heritable MHC class II-associated differences in production of TNFa: Relevance to genetic predisposition to SLE. Proc Natl Acad Sci U S A 1990; 87: 1233-7
18. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13
19. Verweij CL. TNF gene polymorphisms as severity markers in rheumatoid arthritis. Annals Rheum Dis 1999; 58: 120-6
20. Allen R. Polymorphism of the human TNF-alpha promoter: Random variation or functional diversity? Mol Immunol 1999; 36: 1017-27
21. Knight JC, Udalova IA, Hill AV, et al. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999; 22 (2): 120-1
22. van Krugten MV, Huizinga TW, Kaijzel EL, et al. Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes Immun 1999; 1 (2): 91-6
23. Hohler T, Kruger A, Schneider P. A TNFa promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol 1997; 109: 562-5
24. Waldron-Lynch F, Adams C, Amos C, et al. Tumour necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun 2001; 2: 82-7
25. Barton A, John S, Ollier WE, et al. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in caucasians. Arthritis Rheum 2001; 44 (1): 61-5
26. shibue T, Tsuchiya N, Komata T, et al. TNFα 5′flanking region, TNF-RII and HLA-DR81 polymorphisms in Japanese patients with RA. Arthritis Rheum 2000; 43 (4): 753-7
27. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1. Define a family of dominantly inherited autoinflammatory syndromes. Cell 1999: 97 (1): 133-44
28. Buchs N, Silvestri T, di Giovine FS, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis: The rare allele is associated with protection against destruction. Rheumatology (Oxford) 2000; 39 (10): 1126-31
29. Youn J, Hwang SH, Cho CS, et al. Association of the interleukin-4 receptor alpha variant Q576R with Th1/Th2 imbalance in connective tissue disease. Immunogenetics 2000; 51 (8-9): 743-6
30. Hajeer AH, Lazarus M, Turner D, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998; 27 (2): 142-5
31. Huizinga TW, Keijsers V, Yanni G, et al. Are differences in interleukin 10 production associated with joint damage? Rheumatology (Oxford) 2000; 39 (11): 1180-8
32. Cox A, Camp NJ, Cannings C, et al. Combined sib-TDT and TDT provide evidence for linkage of the interleukin-1 gene cluster to erosive rheumatoid arthritis. Hum Mol Genet 1999; 8 (9): 1707-13
33. McDowell TL, Symons JA, Ploski R, et al. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38 (2): 221-8
34. Donn RP, Farhan AJ, Barrett JH, et al. Absence of association between interleukin 1 alpha and oligoarticular juvenile chronic arthritis in UK patients. Rheumatology (Oxford) 1999; 38 (2): 171-5
35. Cantagrel A, Navaux F, Loubet-Lescoulie P, et al. Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42 (6): 1093-100
36. Ghivizzani SC, Kang R, Georgescu HI, et al. Constitutive intraarticular expression of human il-1-beta following gene-transfer to rabbit synovium produces all major pathologies of human rheumatoid-arthritis. Arthritis Rheum 1996; 39: 804
37. Hall MA, McGlinn E, Coakley G, et al. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun 2000; 1 (3): 219-24
38. Pascual M, Nieto A, Mataran L, et al. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000; 1 (5): 338-40
39. Langdon C, Kerr C, Hassen M, et al. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol 2000; 157 (4): 1187-96
40. Nishimoto N, Ito A, Ono M, et al. IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor. Int Immunol 2000; 12 (2): 187-93
41. Aderka D, Le J, Vilcek J. IL-6 inhibits LPS-induced TNF production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989; 143: 3517-23
42. Boe A, Baiocchi M, Carbonatto M, et al. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 1999; 11 (12): 1057-64
43. Wei XQ, Leung BP, Arthur HM, et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166 (1): 517-21
44. Ogueta S, Olazabal I, Santos I, et al. Transgenic mice expressing bovine GH develop arthritic disorder and self-antibodies. J Endocrinol 2000; 165 (2): 321-8
45. Matthys P, Vermeire K, Mitera T, et al. Enhanced immune arthritis in IFN-gamma receptor deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac+1 myeloid cells. J Immunol 1999; 163: 3503-10
46. Moos V, Rudwaleit M, Herzog V, et al. Association of genotypes affecting the expression of interleukin-1 beta or interleukin-1 receptor antagonist with osteoarthritis. Arthritis Rheum 2000; 43 (11): 2417-22
47. Taneja V, Griffiths MM, Luthra H, et al. Modulation of HLA-DQ-restricted collagen-induced arthritis by HLA-DRB1 polymorphism. Int Immunol 1998; 10 (10): 1449-57
48. Lee S, Khare SD, Griffiths MM, et al. HLA-B27 transgenic mice are susceptible to collagen-induced arthritis: Type II collagen as a potential target in human disease. Hum Immunol 2000; 61 (2): 140-7
49. van den Berg WB, van de Loo F, Joosten LA, et al. Animal models of arthritis in NOS2-deficient mice. Osteoarthritis Cartilage 1999; 7 (4): 413-5
50. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 2000; 12 (1): 85-98
51. Tak PP, Firestein GS. NF-kB: A key role in inflammatory diseases. J Clin Invest 2001; 107 (1): 7-11
52. Udalova IA, Richardson A, Denys A, et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000; 20 (24): 9113-9
53. Karin M, Ben NY. Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18 (621): 621-63
54. Shinohara Y, Iwasaki H, Ota N, et al. Novel single nucleotide polymorphisms of the human nuclear factor kappa-B 2 gene identified by sequencing the entire gene. J Hum Genet 2001; 46 (1): 50-1
55. Ishikawa H, Claudio E, Dambach D, et al. Chronic inflammation and susceptibility to bacterial infections in mice lacking the poly-peptide (p)105 precursor (NF-κB-1) but expressing p50. J Exp Med 1998; 187 (7): 985-96
56. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: The second decade. Cell 1995; 83 (6): 835-9
57. Lenardo MJ, Baltimore D. NF-kappa B: A pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58 (2): 227-9
58. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270 (5234): 286-90
59. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270 (5234): 283-6
60. Heck S, Bender K, Kullmann M, et al. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J 1997; 16 (15): 4698-707
61. Ushiyama T, Mori K, Inoue K, et al. Association of oestrogen receptor gene polymorphisms with age at onset of rheumatoid arthritis. Ann Rheum Dis 1999; 58 (1): 7-10
62. Kawasaki T, Ushiyama T, Ueyama H, et al. Polymorphic CAG repeats of the androgen receptor gene and rheumatoid arthritis. Ann Rheum Dis 1999; 58 (8): 500-2
63. Takagi H, Ishiguro N, Iwata H, et al. Genetic association between rheumatoid arthritis and estrogen receptor microsatellite polymorphism. J Rheumatol 2000; 27 (7): 1638-42
64. Uitterlinden AG, Burger H, Huang Q, et al. Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. J Clin Invest 1997; 100 (2): 259-63
65. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996; 10: 1054-72
66. Myerscough A, John S, Barrett JH, et al. Linkage of rheumatoid arthritis to insulin-dependent diabetes mellitus loci: Evidence supporting a hypothesis for the existence of common autoimmune susceptibility loci. Arthritis Rheum 2000; 43 (12): 2771-5
67. Tak PP, Zvaifler NJ, Green DR, et al. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases. Immunol Today 2000; 21 (2): 78-82
68. Tak PP, Smeets TJ, Boyle DL, et al. p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum 1999; 42 (5): 948-53
69. Firestein GS, Echeverri F, Yeo M, et al. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 1997; 94 (20): 10895-900
70. Inazuka M, Tahira T, Horiuchi T, et al. Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 2000; 39 (3): 262-6
71. Kullmann F, Judex M, Neudecker I, et al. Analysis of the p53 tumor suppressor gene in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 1999; 42 (8): 1594-600
72. Pap T, Aupperle KR, Gay S, et al. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum 2001; 44 (3): 676-81
73. Chou CT, Yang JS, Lee MR. Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissue. J Pathol 2001; 193 (1): 110-6
74. Sun Y, Cheung JM, Martel-Pelletier J, et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000; 275 (15): 11327-32
75. Sun Y, Wenger L, Rutter JL, et al. p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 1999; 274 (17): 11535-40
76. Bian J, Sun Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 1997; 17 (11): 6330-8
77. Han Z, Boyle DL, Shi Y, et al. Dominant-negative p53 mutations in rheumatoid arthritis. Arthritis Rheum 1999; 42 (6): 1088-92
78. Davies C, Blake D, Winyard P. Radicals in inflammation: Mediators and modulators. In: Fuchs J, Packer L, editors. Environmental Stressors: Effects on Lung, Skin, Eye, and Immune System Function. New York: Marcel Dekker, 2001: 17-52
79. Grabowski P, Wright P, Van't Hof R, et al. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997: 36 (6): 651-5
80. MacPherson H, Ralston S. Nitric oxide and bone destruction. In: Winyard P, Blake D, Evans C, editors. Free Radicals and Inflammation. Basel: Birkhauser, 2000
81. Winyard P, Blake D. Antioxidants, redox-regulated transcription factors, and inflammation. In: Sies H, editor. Antioxidants in Disease Mechanisms and Therapy. San Diego (CA): Academic Press, 1997: 403-421
82. Raftogianis R, Creveling C, Weinshilboum R, et al. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 2000; 27: 113-24
83. Ollier W, Davies E, Snowden N, et al. Association of homozygosity for glutathione-S-transferase GSTM1 null alleles with the Ro+/La- autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1763-4
84. Morinobu A, Kanagawa S, Koshiba M, et al. Association of the glutathione S-transferase M1 homozygous null genotype with susceptibility to Sjogren's Syndrome in Japanese individuals. Arthritis Rheum 1999; 42: 2612-5
85. Mattey D, Hassell A, Plant M, et al. Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: Comparison with the shared epitope. Ann Rheum Dis 1999; 58 (3): 164-8
86. Estevez A, Crow J, Sampson J, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999; 286 (5449): 2498-500
87. Liochev S, Fridovich I. Copper- and Zinc-containing superoxide dismutase can act as a superoxide reductase and a superoxide oxidase. J Biol Chem 2000; 275: 38482-5
88. Butcher R, Bitensky L, Cashman B, et al. Differences in the redox balance in human rheumatoid and non-rheumatoid synovial lining cells. Beitr Path 1973; 148: 265-74
89. Ukkola O, Erkkila P, Savolainen M, et al. Lack of association between polymorphisms of catalase, copper-zinc superoxide dismutase (SOD), extracellular SOD and endothelial nitric oxide synthase genes and macroangiopathy in patients with type 2 diabetes mellitus. J Intern Med 2001; 249 (5): 451-9
90. Mattey DL, Hassell AB, Dawes PT, et al. Influence of polymorphism in the manganese superoxide dismutase locus on disease outcome in rheumatoid arthritis: Evidence for interaction with glutathione S-transferase genes. Arthritis Rheum 2000; 43 (4): 859-64
91. Puntarulo S, Cederbaum A. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. Free Radic Biol Med 1998; 24: 1324-30
92. Beyeler C, Daly A, Armstrong M, et al. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: Influence of drug therapy and disease activity. J Rheumatol 1994; 21: 1034-8
93. Baer A, McAllister C, Wilkinson G, et al. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 843-50
94. Beyeler C, Armstrong M, Bird H, et al. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996; 55 (1): 66-8
95. Brown M, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000; 9 (11): 1563-6
96. Povey A, Guppy M, Wood M, et al. Cytochrome P2 polymorphisms and susceptibility to scleroderma following exposure to organic solvents. Arthritis Rheum 2001; 44: 662-5
97. Layton M, Jones P, Alldersea J, et al. The therapeutic response to D-penicillamine in rheumatoid arthritis: Influence of glutathione S-transferase polymorphisms. Rheumatology 1999; 38 (1): 43-7
98. Aithal G, Day C, Leathart J, et al. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511-8
99. Knekt P, Heliovaara M, Aho K, et al. Serum selenium, serum alpha-tocopherol, and the risk of rheumatoid arthritis. Epidemiology 2000; 11 (4): 402-5
100. Comstock G, Burke A, Hoffman S, et al. Serum concentrations of alpha tocopherol, beta carotene, and retinal preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1997; 56 (5): 323-5
101. Heliovaara M, Knekt P, Aho K, et al. Serum antioxidantsand risk of rheumatoid arthritis. Arthritis Rheum 1994; 53: 51-3
102. Rideout WM, Coetzee GA, Olumi AF, et al. 5 Methyl cytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990; 249: 1288-90
103. Roivainen A, Jalava J, Pirila L, et al. H-ras oncogene point mutations in arthritic synovium. Arthritis Rheum 1996; 39: 992
104. Hmdacha A, Bedoya FJ, Sobrino F, et al. Methylation-dependent gene silencing induced by IL-1b via nitric oxide production. J Exp Med 1999; 190: 1595-603
105. Feldmann M, Brennan F, Maini R. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397-440
106. Feldmann M, Elliott M, Woody J, et al. Anti-TNF alpha therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283-350
107. Nunez MO, Ripoll NC, Carneros MJA, et al. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol 2001; 96 (5): 1665-6
108. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57 (10): 1885-8
109. Chernajovsky Y. Gene transfer as therapy for rheumatoid arthritis: Why, what and how? Rheumatology 1999; 38 (9): 804-6
110. Chernajovsky Y, Gould D, Annenkov A, et al. Immunotherapy of auto-immune diseases by gene transfer. Biochem Soc Trans 1999; 27 (6): 869-73
111. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for rheumatoid arthritis. Springer Semin Immunopathol 1998; 20 (1-2): 197-209
112. Chernajovsky Y, Annenkov A, Herman C, et al. Gene therapy for rheumatoid arthritis: Theoretical considerations. Drugs Aging 1998; 12 (1): 29-41
113. Chernajovsky Y, Feldmann M, Maini RN. Gene therapy of rheumatoid arthritis via cytokine regulation: Future perspectives. Br Med Bull 1995; 51 (2): 503-16
114. Gould DJ, Berenstein M, Dreja H, et al. A novel doxycycline inducible autoregulatory plasmid which displays 'on'/'off' regulation suited to gene therapy applications. Gene Ther 2000; 7 (24): 2061-70
115. Annenkov AE, Moyes SP, Eshhar Z, et al. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonR1-signaling gamma subunit. J Immunol 1998; 161 (12): 6604-13
116. Annenkov A, Chernajovsky Y. Engineering mouse T lymphocytes specific to type II collagen by transduction with a chimeric receptor consisting of a single chain, Fv and TCR zeta. Gene Ther 2000; 7 (8): 714-22
117. Evans CH, Ghivizzani SC, Herndon JH, et al. Clinical trials in the gene therapy of arthritis. Clin Orthop 2000; 379: S300-7